Grace Therapeutics, Inc. (GRCE) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $2.11, GRCE has negative trailing earnings (P/E not meaningful) and an ROE of -35.78%. Market capitalisation stands at $34M.
Balance sheet quality for GRCE: current ratio of 8.1. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $2.11 |
| Market Cap | $34M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.74 |
| EV / EBITDA | -0.80 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -35.78% |
| Return on Invested Capital | -48.75% |
| Return on Assets | -42.84% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 11.47 |
| Piotroski F-Score | 1 |
| Altman Z-Score | 11.56 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| GRCE | Grace Therapeutics, Inc. | $34M | 0.74 | -35.8% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $129.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $129.0B | 29.40 | 6.39 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.9B | 18.91 | 2.58 | 13.8% |
| REGN | Regeneron Pharmaceuticals, Inc. | $80.9B | 18.61 | 2.54 | 13.8% |
| ARGX | argenx SE | $61.6B | 36.12 | 7.36 | 21.7% |
| MRNA | Moderna, Inc. | $61.1B | 9.14 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $40.6B | 15.14 |
Price Performance
| 1 month | -1.40% |
| 3 months | -11.34% |
| Year-to-date | -39.02% |
| 1 year | -31.94% |
52-Week Range
| 52-week High | $5.18 |
| 52-week Low | $1.79 |
| Avg Volume (90d) | 235K |
Related companies: ABVC · ATNM · CALC · LTRN · LVTX · OKUR · PDSB
Explore sector: Healthcare · Biotechnology
More sections of GRCE: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks